Lack of response to anti-PDL1 therapy has been associated with a TGFβ signature in fibroblasts in urothelial cancer, and concurrent TGFβ blockade facilitated T-cell penetration, provoking anti-tumour immunity and tumour regression [81,132]. The gene discussed is TGFB1; the disease is neoplasm.